Optical Genome Mapping in Hematological Malignancies

Last updated: August 16, 2021
Sponsor: University Hospital, Brest
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hematologic Neoplasms

Neoplasms

Lymphocytic Leukemia, Acute

Treatment

N/A

Clinical Study ID

NCT05009537
CARTOGEN - 29BRC21.0211
  • All Genders

Study Summary

Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Minor/Major Patients
  • Patients with suspected hemopathies for whom we receive a sample for diagnosis in thechromosomal genetics laboratory or for whom a diagnosis of hemopathy has already beenmade.
  • No objection made or consent given

Exclusion

Exclusion Criteria:

  • Patients under judicial protection (guardianship, curatorship, ...),
  • Refusal to participate

Study Design

Total Participants: 200
Study Start date:
September 01, 2021
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • CHRU de Brest

    Brest, 29609
    France

    Active - Recruiting

  • CH Morlaix, service d'hémato clinique

    Morlaix,
    France

    Active - Recruiting

  • CHIC, service d'hémato clinique

    Quimper,
    France

    Active - Recruiting

  • CH St Brieuc, service d'hémato clinique

    Saint-Brieuc,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.